CORESTATE Capital (CCAP) Stock Price, News & Analysis

Company Overview

CORESTATE Capital Holding S.A. is a real estate investment firm specializing in investments in small to medium sized residential portfolios and commercial real estate markets. The firm seeks to invest in an "anti-cyclical" manner in Europe and expand its club-style deals from purely opportunistic to core-plus and value-add investments. The firm offers investment products in real estate funds, co-investments, and club deals. It prefers to invest in Central Europe, Austria, Switzerland, and Germany. CORESTATE Capital Holding S.A. was founded in 2006 and is based in Luxembourg, Luxembourg with additional offices in Zug, Switzerland; London, United Kingdom; Frankfurt, Germany; and Singapore. CORESTATE Capital Holding S.A. operates as a subsidiary of Flygon Holding LLC.

Key Stats

• Today's Range: €0.38 to €0.38
• 50-Day Range: €0.36 to €0.42
• 52-Week Range: €0.26 to €0.76
• Volume: 24,414 shs
• Average Volume: N/A
• Market Capitalization: $63.02 million
• P/E Ratio: N/A
• Dividend Yield: 657.89%
• Price Target: N/A
• Consensus Rating: N/A

CCAP Stock Analysis - Frequently Asked Questions

How have CCAP shares performed this year?

CORESTATE Capital's stock was trading at €0.36 at the beginning of 2025. Since then, CCAP shares have increased by 5.6% and is now trading at €0.38.
View the best growth stocks for 2025 here.

What other stocks do shareholders of CORESTATE Capital own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CORESTATE Capital investors own include bluebird bio (BLUE), Cisco Systems (CSCO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA), Aravive (ARAV), Athersys (ATHX) and Atara Biotherapeutics (ATRA).

Industry, Sector and Symbol

• Stock Exchange: ETR
• Sector: Real Estate
• Industry: Real Estate Services
• Sub-Industry: Financial Services
• Current Symbol: ETR:CCAP
• CUSIP: N/A
• CIK: N/A
• Web: www.corestate-capital.ch
• Phone: 352 26 6372 20
• Fax: N/A
• Employees: 446
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): (€21.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: -0.01
• Net Income: $-3,499,186,007.47
• Net Margins: -1,143.36%
• Pretax Margin: N/A
• Return on Equity: -269.30%
• Return on Assets: -7.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: 0.17

Sales & Book Value

• Annual Sales: $306.04 million
• Price / Sales: 0.21
• Cash Flow: €0.64 per share
• Price / Cash Flow: 0.60
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 165,831,023
• Free Float: N/A
• Market Cap: $63.02 million
• Optionable: Not Optionable
• Beta: 1.03